Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents - A status paper;Nephrogene systemische fibrose nach anwendung gadoliniumhaltiger kontrastmittel - Ein statuspapier zum aktuellen stand des wissens

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 179, Issue 6, 2007, Pages 613-617

  Heinrich, Marc ^a   Uder, Michael ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Contrast agents; Drugs reactions; MR imaging

Indexed keywords

GADODIAMIDE; GADOLINIUM;

ARTICLE; CHRONIC KIDNEY FAILURE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FIBROSIS; LIVER TRANSPLANTATION; NEPHROGENIC FIBROSING DERMOPATHY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SCLERODERMA;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY; KIDNEY DISEASES;

EID: 34447617519     PISSN: 14389029     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963166     Document Type: Article

References (35)

1. Bundesinstitut für Arzneimittel und Medizinprodukte. Pharmakovigilanz - Aktuell: Gadodiamid (Omniscan®) und nephrogene fibrosierende Dermopathie/nephrogene systemische Fibrose (NFD/NSF). Published 12.01.2007. Accessed 17.02.2007. http://www.bfarm.de/cln_043/nn_828832/DE/ Pharmakovigilanz/aktuell/gadodiamid_dermatopathie.html_=true
2. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-1108
3. Marckmann P, Skov L, Rossen K et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-2362
4. Bundesinstitut für Arzneimittel und Medizinprodukte. Pharmakovigilanz - Aktuell: Omniscan® (Gadodiamid) und andere Gadoliniumhaltige MRT-Kontrastmittel: Anwendungsbeschränkungen für Patienten mit eingeschrankter Nierenfunktion und weitere Warnhinweise angeordnet. Published 08.02.2007. Accessed 17.02.2007. http://www.bfarm.de/ cln_043/nn_828832/DE/Pharmakovigilanz/aktuell/ gadodiamid__nierenfunktionseinschraenkung.html_=true
5. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003; 15: 785-790
6. Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005; 46: 763-765
7. Kuo PH, Kanal E, Abu-Alfa AK et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007; Epub ahead of print
8. Cowper SE, Robin HS, Steinberg SM et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1001
9. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005; 46: 754-759
10. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006; 18: 614-617
11. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006; 130: 209-212
12. Sadowski EA, Bennett LK, Chan MR et al. Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation. Radiology 2007; Epub ahead of print:
13. Cowper SE, Bucala R, LeBoit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis - setting the record straight. Semin Arthritis Rheum 2006; 35: 208-210
14. Grobner T. Reply. Nephrol Dial Transplant 2006; 21: 3604-3605
15. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56: 27-30
16. High WA, Ayers RA, Chandler J et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 21-26
17. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; Epub ahead of print
18. Dharnidharka VR, Wesson SK, Fennell RS. Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 2006; Epub ahead of print:
19. Khurana A, Runge VM, Narayanan M et al. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan). Invest Radiol 2007; 42: 139-145
20. Broome DR, Girguis MS, Baron PW et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007; 188: 586-592
21. Yerram P, Saab G, Karuparthi PR et al. Nephrogenic systemic fibrosis: A mysterious disease in patients with renal failure - Role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007; Epub ahead of print
22. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; Epub ahead of print
23. Roditi G, Collidge TA, Thomson PC et al. A retrospective case-control study of gadolinium-enhanced magnetic resonance imaging and nephrogenic systemic fibrosis in patients with renal failure. ECR 2007; B-100
24. U.S. Food and Drug Administration. Information for Healthcare Professionals: Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging Scans (marketed as Omniscan, OptiMARK, Magnevist, Pro-Hance, and MultiHance). Published 27.12.2006. Updated 08.01.2007. Accessed 17.02.2007. http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200612HCP.htm
25. Cowper SE. Nephrogenic Fibrosing Dermopathy (NFD/NSF Website). Last updated 07.02.2007. Accessed 17.02.2007. http://www.icnfdr.org; Published 2001-2007
26. Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol 2006; 16: 2619-2621
27. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5: 491-502
28. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003; 14: 426-435
29. Idee JM, Port M, Raynal I et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006; 20: 563-576
30. White GW, Gibby WA, Tweedle MF. Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd (HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006; 41: 272-278
31. Sieber M, Pietsch H, Walter J et al. Are gadolinium contrast agents a possible trigger for the development of nephrogenic fibrosing dermopathy? ECR 2007; B-099
32. Thomsen HS. European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 2007; 17: 70-76
33. Rote-Hand-Brief zu Omniscan (Gadodiamid). Wichtige Information zur Arzneimittelsicherheit: Omniscan und nephrogene systemische Fibrose. Published 08.02.2007. Accessed 17.02.2007. http://www.bfarm.de/cln_042/nn_828832/DE/ Pharmakovigilanz/aktuell/gadodiamid__nierenfunktionseinschraenkung.html_=true
34. Heinrich M, Uder M. Hydrierung zur Prävention der Kontrastmittel-induzierten Nephropathie: Ein Update. Fortschr Röntgenstr 2006; 178: 378-384
35. Heinrich MC, Kuhlmann MK, Kohlbacher S et al. Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study. Radiology 2007; 242: 425-434